Standout Papers

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated ... 2004 2026 2011 2018 3.4k
  1. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (2004)
    William Pao, Vincent A. Miller et al. Proceedings of the National Academy of Sciences
  2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005)
    William Pao, Vincent A. Miller et al. PLoS Medicine
  3. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers (2013)
    Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research
  4. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017)
    Aaron M. Goodman, Shumei Kato et al. Molecular Cancer Therapeutics
  5. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  6. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  7. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005)
    William Pao, Gregory J. Riely et al. PLoS Medicine
  8. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib (2005)
    David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology
  9. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2005)
    Roy S. Herbst, Diane Prager et al. Journal of Clinical Oncology
  10. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens (2000)
    Frank V. Fossella, Russell F. DeVore et al. Journal of Clinical Oncology
  11. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (2012)
    Vincent A. Miller, Vera Hirsh et al. The Lancet Oncology
  12. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006)
    Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research
  13. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer (2009)
    David M. Jackman, William Pao et al. Journal of Clinical Oncology
  14. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer (2004)
    Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology
  15. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006)
    Gregory J. Riely, William Pao et al. Clinical Cancer Research
  16. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation (2012)
    Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery
  17. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions (2005)
    William Pao, Vincent A. Miller Journal of Clinical Oncology
  18. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations (2011)
    Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology
  19. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010)
    Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research
  20. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011)
    Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research
  21. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019)
    Jason K. Sicklick, Shumei Kato et al. Nature Medicine

Immediate Impact

2 by Nobel laureates 40 from Science/Nature 253 standout
Sub-graph 1 of 14

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Pancreatic cancer: Advances and challenges
2023 Standout
17 intermediate papers

Works of Vincent A. Miller being referenced

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
2019
Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes
2014
and 16 more

Author Peers

Author Last Decade Papers Cites
Vincent A. Miller 30167 29326 10353 15829 476 44.8k
Tony Mok 38626 34880 12185 15477 671 55.0k
Pasi A. Jänne 39885 35323 13408 25164 645 60.0k
Tetsuya Mitsudomi 22217 17840 8353 14384 530 35.9k
William Pao 23852 20819 7904 13960 231 35.0k
Gregory J. Riely 23302 19166 6603 10730 358 30.7k
José Baselga 13824 25287 9567 19503 482 45.7k
Yasushi Yatabe 14927 14366 8535 11845 632 31.1k
Enriqueta Felip 22212 22899 5519 8796 776 32.5k
Fortunato Ciardiello 11605 21501 5351 13119 626 33.5k
Kazuhiko Nakagawa 20348 21732 4358 9723 810 31.6k

All Works

Loading papers...

Rankless by CCL
2026